Huseyin Naci

12PUBLICATIONS
28CO-AUTHORS
Cancer diagnosisPharmacogenomicsMolecular targetsPacific Peoples midwifery and paediatricsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Dec 23, 2025
Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational study and economic evaluation.

Huseyin Naci, Mahnum Shahzad, Peter Murphy

|Dec 17, 2025
Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study.

Rylee McGonigle, Huseyin Naci, Maximilian Siebert

|Mar 29, 2023
Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe.

Courtney Davis, Anita K Wagner, Maximilian Salcher-Konrad

|Jun 06, 2022
Post-Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004-2014.

Avi Cherla, Elias Mossialos, Maximilian Salcher-Konrad

|Feb 15, 2022
The Cyprus Women's Health Research (COHERE) initiative: normative data from the SF-36v2 questionnaire for reproductive aged women from the Eastern Mediterranean.

B Swift, H Naci, B Taneri

|Apr 03, 2020
Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe.

Rick A Vreman, Huseyin Naci, Wim G Goettsch

Pageof 2

Frequent Collaborators

2 joint publications

Sanjay Basu

2 joint publications

Maximilian Salcher-Konrad

2 joint publications

Anita K Wagner

1 joint publications

B Swift